Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences, expressed optimism about the preclinical efficacy results and the potential of their AI platform in developing effective cancer vaccines.

CK Life Sciences will present new preclinical study data on investigational cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, running from April 25 to April 30.

Additionally, CK Life Sciences will highlight its AI-powered platform designed to enhance the immunogenicity and clinical effectiveness of these cancer vaccines.

Among the vaccines in development, seviprotimut-L is in the final research stage for treating stage IIB or IIC melanoma post-surgery.

The company will showcase data on cancer vaccines targeting PRAME, PD-L1, B7-H3, and Claudin 6, proteins linked to various cancers, including melanoma and breast cancer.

Key poster presentations will include studies on combined PD-L1 and B7-H3 vaccination effects, as well as findings on PD-L1-PRAME dual vaccines and Claudin 6 vaccines in colon cancer, scheduled for April 27 and 28.

PRAME is primarily expressed in melanoma, liver cancer, and leukemia; PD-L1 is an immune checkpoint protein that inhibits T cell activation; B7-H3 modulates T cell responses; and Claudin 6 is associated with tumor progression in several cancers.

The press release includes a disclaimer about forward-looking statements and clarifies that it does not constitute investment or medical advice.

The AACR Annual Meeting is a significant event for the global cancer research community, with the previous year's meeting attracting over 29,000 participants from around the world.

The full abstracts from the presentations will be available through the AACR Online Itinerary Planner.